{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:38:04Z","timestamp":1793147884906,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00393-020-00750-1","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T16:05:16Z","timestamp":1581609916000},"page":"785-796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis","Relative Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, Upadacitinib und Filgotinib im Vergleich zu Adalimumab bei Patienten mit aktiver rheumatoider Arthritis"],"prefix":"10.1007","volume":"79","author":[{"given":"Young Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwan Gyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"issue":"10055","key":"750_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen\u00a0JS, Aletaha\u00a0D, McInnes\u00a0IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"750_CR2","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.1780331001","volume":"33","author":"DT Felson","year":"1990","unstructured":"Felson\u00a0DT, Anderson\u00a0JJ, Meenan\u00a0RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33:1449\u20131461","journal-title":"Arthritis Rheum"},{"key":"750_CR3","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.20278","volume":"50","author":"JM Kremer","year":"2004","unstructured":"Kremer\u00a0JM (2004) Toward a\u00a0better understanding of methotrexate. Arthritis Rheum 50:1370\u20131382","journal-title":"Arthritis Rheum"},{"key":"750_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","volume":"41","author":"D Aletaha","year":"2002","unstructured":"Aletaha\u00a0D, Smolen\u00a0JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 41:1367\u20131374","journal-title":"Rheumatology (Oxford)"},{"issue":"22","key":"750_CR5","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"P Lipsky","year":"2000","unstructured":"Lipsky\u00a0P, van der Heijde\u00a0D, St. Clair\u00a0E, Furst\u00a0D, Breedveld\u00a0F, Kalden\u00a0J, Smolen\u00a0J, Weisman\u00a0M, Emery\u00a0P, Feldmann\u00a0M (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N\u00a0Engl J Med 343(22):1594\u20131602","journal-title":"N Engl J Med"},{"key":"750_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi\u00a0K, Laurence\u00a0A, O\u2019Shea\u00a0JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273\u2013287","journal-title":"Immunol Rev"},{"key":"750_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","volume":"111","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski\u00a0R Jr (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784\u2013803","journal-title":"Pharmacol Res"},{"key":"750_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian\u00a0PS, Flanagan\u00a0ME, Ball\u00a0DJ et\u00a0al (2003) Prevention of organ allograft rejection by a\u00a0specific Janus kinase 3 inhibitor. Science 302:875\u2013878","journal-title":"Science"},{"key":"750_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2010.05.020","volume":"400","author":"JE Chrencik","year":"2010","unstructured":"Chrencik\u00a0JE, Patny\u00a0A, Leung\u00a0IK et al (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP\u20116. J\u00a0Mol Biol 400:413\u2013433","journal-title":"J Mol Biol"},{"key":"750_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer\u00a0DM, Jesson\u00a0MI, Li\u00a0X et al (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J\u00a0Inflamm (Lond) 7:41","journal-title":"J Inflamm (Lond)"},{"key":"750_CR11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi\u00a0JG, Chen\u00a0X, Lee\u00a0F, Emm\u00a0T, Scherle\u00a0PA, Lo\u00a0Y, Punwani\u00a0N, Williams\u00a0WV, Yeleswaram\u00a0S (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J\u00a0Clin Pharmacol 54:1354\u20131361","journal-title":"J Clin Pharmacol"},{"key":"750_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi\u00a0K, Laurence\u00a0A, O\u2019Shea\u00a0JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273\u2013287","journal-title":"Immunol. Rev."},{"key":"750_CR13","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3904\/kjim.2014.29.5.656","volume":"29","author":"GG Song","year":"2014","unstructured":"Song\u00a0GG, Bae\u00a0S\u2011C, Lee\u00a0YH (2014) Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a\u00a0meta-analysis of randomized controlled trials. Korean J Intern Med 29:656","journal-title":"Korean J Intern Med"},{"key":"750_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00393-016-0254-4","volume":"77","author":"Y Lee","year":"2018","unstructured":"Lee\u00a0Y, Bae\u00a0S\u2011C (2018) Comparative efficacy and safety of baricitinib 2 and 4\u202fmg in patients with active rheumatoid arthritis. Z\u00a0Rheumatol 77:335\u2013342","journal-title":"Z Rheumatol"},{"key":"750_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00001721-199404000-00003","volume":"5","author":"T Nakase","year":"1994","unstructured":"Nakase\u00a0T, Wada\u00a0H, Minamikawa\u00a0K et al (1994) Increased activated protein C\u2011protein C inhibitor complex level in patients positive for lupus anticoagulant. Blood Coagul Fibrinolysis 5:173\u2013177","journal-title":"Blood Coagul Fibrinolysis"},{"key":"750_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R, Mysler\u00a0E, Hall\u00a0S, Kivitz\u00a0AJ, Moots\u00a0RJ, Luo\u00a0Z, DeMasi\u00a0R, Soma\u00a0K, Zhang\u00a0R, Takiya\u00a0LJTL (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468","journal-title":"Lancet"},{"key":"750_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor\u00a0PC, Keystone\u00a0EC, van der Heijde\u00a0D et\u00a0al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N\u00a0Engl J Med 376:652\u2013662","journal-title":"N Engl J Med"},{"key":"750_CR18","volume-title":"A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate","author":"R Fleischmann","year":"2018","unstructured":"Fleischmann\u00a0R, Pangan\u00a0AL, Mysler\u00a0E, Bessette\u00a0L, Peterfy\u00a0C, Durez\u00a0P, Ostor\u00a0A, Li\u00a0Y, Zhou\u00a0Y, Othman\u00a0AA (2018) A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Arthritis & Rheumatology, Hoboken"},{"key":"750_CR19","volume-title":"Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results","author":"B Combe","year":"2019","unstructured":"Combe\u00a0B, Kivitz\u00a0A, Tanaka\u00a0Y, van der Heijde\u00a0D, Matzkies\u00a0F, Bartok\u00a0B, Ye\u00a0L, Guo\u00a0Y, Tasset\u00a0C, Sundy\u00a0J (2019) Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results"},{"key":"750_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4078\/jrd.2018.25.3.169","volume":"25","author":"YH Lee","year":"2018","unstructured":"Lee\u00a0YH (2018) Association between the neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and rheumatoid arthritis and their correlations with the disease activity: a meta-analysis. J\u00a0Rheum Dis 25:169\u2013178","journal-title":"J Rheum Dis"},{"key":"750_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3343\/alm.2015.35.3.283","volume":"35","author":"YH Lee","year":"2015","unstructured":"Lee\u00a0YH (2015) Meta-analysis of genetic association studies. Ann Lab Med 35:283\u2013287","journal-title":"Ann Lab Med"},{"key":"750_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4078\/jrd.2017.24.4.211","volume":"24","author":"YH Lee","year":"2017","unstructured":"Lee\u00a0YH, Song\u00a0GG (2017) Comparative efficacy and safety of secukinumab and adalimumab in patients with active ankylosing spondylitis: a\u00a0Bayesian network meta-analysis of randomized controlled trials. J\u00a0Rheum Dis 24:211\u2013219","journal-title":"J Rheum Dis"},{"key":"750_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.1780350502","volume":"35","author":"MC Hochberg","year":"1992","unstructured":"Hochberg\u00a0MC, Chang\u00a0RW, Dwosh\u00a0I, Lindsey\u00a0S, Pincus\u00a0T, Wolfe\u00a0F (1992) The American college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35:498\u2013502","journal-title":"Arthritis Rheum"},{"key":"750_CR24","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/art.24123","volume":"59","author":"D Aletaha","year":"2008","unstructured":"Aletaha\u00a0D, Landewe\u00a0R, Karonitsch\u00a0T, Bathon\u00a0J, Boers\u00a0M, Bombardier\u00a0C, Bombardieri\u00a0S, Choi\u00a0H, Combe\u00a0B, Dougados\u00a0M (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations. Arthritis Care Res 59:1371\u20131377","journal-title":"Arthritis Care Res"},{"key":"750_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad\u00a0AR, Moore\u00a0RA, Carroll\u00a0D, Jenkinson\u00a0C, Reynolds\u00a0DJM, Gavaghan\u00a0DJ, McQuay\u00a0HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"750_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher\u00a0D, Liberati\u00a0A, Tetzlaff\u00a0J, Altman\u00a0DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269","journal-title":"Ann Intern Med"},{"key":"750_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/2046-4053-3-110","volume":"3","author":"S Brown","year":"2014","unstructured":"Brown\u00a0S, Hutton\u00a0B, Clifford\u00a0T, Coyle\u00a0D, Grima\u00a0D, Wells\u00a0G, Cameron\u00a0C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses\u2014an overview and application of NetMetaXL. Syst Rev 3:110","journal-title":"Syst Rev"},{"key":"750_CR28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell\u00a0DM, Ades\u00a0A, Higgins\u00a0J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897","journal-title":"BMJ"},{"key":"750_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti\u00a0G, Ades\u00a0A, Ioannidis\u00a0JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J\u00a0Clin Epidemiol 64:163\u2013171","journal-title":"J Clin Epidemiol"},{"key":"750_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias\u00a0S, Welton\u00a0NJ, Sutton\u00a0AJ, Caldwell\u00a0DM, Lu\u00a0G, Ades\u00a0A (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33:641\u2013656","journal-title":"Med. Decis. Making"},{"key":"750_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"J Higgins","year":"2012","unstructured":"Higgins\u00a0J, Jackson\u00a0D, Barrett\u00a0J, Lu\u00a0G, Ades\u00a0A, White\u00a0I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98\u2013110","journal-title":"Res Synth Methods"},{"key":"750_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G Valkenhoef","year":"2012","unstructured":"Valkenhoef\u00a0G, Lu\u00a0G, Brock\u00a0B, Hillege\u00a0H, Ades\u00a0A, Welton\u00a0NJ (2012) Automating network meta-analysis. Res Synth Methods 3:285\u2013299","journal-title":"Res Synth Methods"},{"key":"750_CR33","doi-asserted-by":"publisher","first-page":"666","DOI":"10.7326\/M15-2521","volume":"164","author":"L Trinquart","year":"2016","unstructured":"Trinquart\u00a0L, Attiche\u00a0N, Bafeta\u00a0A, Porcher\u00a0R, Ravaud\u00a0P (2016) Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trialsuncertainty in treatment rankings from network meta-analyses. Ann Intern Med 164:666\u2013673","journal-title":"Ann Intern Med"},{"key":"750_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven\u00a0RF, Fleischmann\u00a0R, Cohen\u00a0S et\u00a0al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N\u00a0Engl J Med 367:508\u2013519","journal-title":"N Engl J Med"},{"key":"750_CR35","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00296-014-2994-2","volume":"34","author":"F Catal\u00e1-L\u00f3pez","year":"2014","unstructured":"Catal\u00e1-L\u00f3pez\u00a0F, Tob\u00edas\u00a0A, Cameron\u00a0C, Moher\u00a0D, Hutton\u00a0B (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34:1489\u20131496","journal-title":"Rheumatol Int"},{"key":"750_CR36","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-014-2645-8","volume":"33","author":"GG Song","year":"2014","unstructured":"Song\u00a0GG, Bae\u00a0S\u2011C, Lee\u00a0YH (2014) Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a\u00a0meta-analysis. Clin Rheumatol 33:1715\u20131724","journal-title":"Clin. Rheumatol."},{"key":"750_CR37","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00296-010-1526-y","volume":"31","author":"YH Lee","year":"2011","unstructured":"Lee\u00a0YH, Bae\u00a0SC, Song\u00a0GG (2011) The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a\u00a0systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 31:1493\u20131499","journal-title":"Rheumatol Int"},{"key":"750_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11033-011-0712-7","volume":"39","author":"YH Lee","year":"2012","unstructured":"Lee\u00a0YH, Bae\u00a0SC, Choi\u00a0SJ, Ji\u00a0JD, Song\u00a0GG (2012) Associations between interleukin-10 polymorphisms and susceptibility to rheumatoid arthritis: a\u00a0meta-analysis. Mol Biol Rep 39:81\u201387","journal-title":"Mol Biol Rep"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00750-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-020-00750-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00750-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:53:37Z","timestamp":1613091217000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-020-00750-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["750"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00750-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"13 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"Y.H.\u00a0Lee and G.G.\u00a0Song have no financial or non-financial conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}